LONDON—AstraZeneca Plc on Thursday struck a deal with the firm behind Imperial College London’s experimental COVID-19 vaccine to develop and sell drugs based on its self-amplifying RNA technology platform in other disease areas. Under the deal, VaxEquity, a startup founded by Imperial vaccinologist Robin Shattock, could receive up to $195 million if certain milestones are…